Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11642361 Nucleoside phosphoramidate prodrugs

Patent 11642361 was granted and assigned to Gilead Sciences on May, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Gilead Sciences

Current Assignee

Gilead Sciences

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

116423610

Patent Inventor Names

Dhanapalan Nagarathnam0

Jinfa Du0

Michael Joseph Sofia0

Peiyuan Wang0

Date of Patent

May 9, 2023

Patent Application Number

170772670

Date Filed

October 22, 2020

Patent Citations Received

‌

US Patent 11975016 2′-substituted-N

‌

US Patent 12121529 Nucleoside phosphoramidate prodrugs

‌

US Patent 12006340 Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus

Patent Primary Examiner

‌

Patrick T. Lewis

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11642361 Nucleoside phosphoramidate prodrugs

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API